ChromaDex (CDXC)
(Delayed Data from NSDQ)
$3.66 USD
+0.28 (8.28%)
Updated May 14, 2024 04:00 PM ET
After-Market: $3.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CDXC 3.66 +0.28(8.28%)
Will CDXC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CDXC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDXC
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
CDXC: What are Zacks experts saying now?
Zacks Private Portfolio Services
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
Other News for CDXC
ChromaDex price target raised by 30c at Ladenburg, here's why
ChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue Estimates
Chromadex Poised for Continued Growth; Selvaraju Reiterates Buy Rating with $6 Target
ChromaDex Corp (CDXC) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...
ChromaDex: Q1 Earnings Snapshot